These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 16277084

  • 1. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G.
    Praxis (Bern 1994); 2005 Oct 19; 94(42):1633-8. PubMed ID: 16277084
    [Abstract] [Full Text] [Related]

  • 2. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
    Bonuccelli U, Colzi A, Del Dotto P.
    Clin Neuropharmacol; 2002 Oct 19; 25(1):1-10. PubMed ID: 11852289
    [Abstract] [Full Text] [Related]

  • 3. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A, Sanchez-Ramos J.
    Mov Disord; 1996 May 19; 11(3):327-9. PubMed ID: 8723153
    [No Abstract] [Full Text] [Related]

  • 4. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM, Houeto JL.
    Rev Neurol (Paris); 2002 Jul 19; 158(6-7):744-5. PubMed ID: 12486908
    [Abstract] [Full Text] [Related]

  • 5. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T.
    J Neurol; 2002 Sep 19; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [Abstract] [Full Text] [Related]

  • 6. Parkinson's disease.
    Clarke C, Moore AP.
    Clin Evid; 2002 Jun 19; (7):1208-20. PubMed ID: 12230738
    [No Abstract] [Full Text] [Related]

  • 7. Parkinson's disease.
    Clarke C, Moore A.
    Clin Evid; 2002 Dec 19; (8):1370-85. PubMed ID: 12603943
    [No Abstract] [Full Text] [Related]

  • 8. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B.
    Mov Disord; 1995 Sep 19; 10(5):668-71. PubMed ID: 8552122
    [Abstract] [Full Text] [Related]

  • 9. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P, Konitsiotis S, Antonini A.
    Expert Rev Neurother; 2015 Feb 19; 15(2):207-13. PubMed ID: 25578445
    [Abstract] [Full Text] [Related]

  • 10. Future therapies for Parkinson's disease.
    Hauser RA, Lyons KE.
    Neurol Clin; 2004 Oct 19; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract] [Full Text] [Related]

  • 11. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J, Pagonabarraga J.
    Drug Saf; 2010 Feb 01; 33(2):147-61. PubMed ID: 20082541
    [Abstract] [Full Text] [Related]

  • 12. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec 01; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

  • 13. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F, Sternon J, Zegers de Beyl D.
    Rev Med Brux; 2000 Dec 01; 21(6):493-9. PubMed ID: 11194495
    [Abstract] [Full Text] [Related]

  • 14. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Dec 01; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 15. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
    Kuhn W, Müller T.
    Fortschr Neurol Psychiatr; 1997 Aug 01; 65(8):361-74. PubMed ID: 9378449
    [Abstract] [Full Text] [Related]

  • 16. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U, Del Dotto P, Rascol O.
    Parkinsonism Relat Disord; 2009 Dec 01; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [Abstract] [Full Text] [Related]

  • 17. Controversies in the treatment of Parkinson's disease.
    Hely MA, Morris JG.
    Curr Opin Neurol; 1996 Aug 01; 9(4):308-13. PubMed ID: 8858190
    [Abstract] [Full Text] [Related]

  • 18. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O.
    Eur J Neurol; 2011 Mar 01; 18 Suppl 1():3-10. PubMed ID: 21255197
    [Abstract] [Full Text] [Related]

  • 19. Long-term studies of dopamine agonists.
    Hubble JP.
    Neurology; 2002 Feb 26; 58(4 Suppl 1):S42-50. PubMed ID: 11909984
    [Abstract] [Full Text] [Related]

  • 20. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M, Riederer P.
    Nervenarzt; 2003 Mar 26; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.